116 related articles for article (PubMed ID: 26985148)
1. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.
Popadiuk C; Gauvreau CL; Bhavsar M; Nadeau C; Asakawa K; Flanagan WM; Wolfson MC; Coldman AJ; Memon S; Fitzgerald N; Lacombe J; Miller AB
Curr Oncol; 2016 Feb; 23(Suppl 1):S56-63. PubMed ID: 26985148
[TBL] [Abstract][Full Text] [Related]
2. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
6. Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical.
Mittendorf T; Nocon M; Roll S; Mühlberger N; Sroczynski G; Siebert U; Willich SN; von der Schulenburg JM
GMS Health Technol Assess; 2007 Sep; 3():Doc08. PubMed ID: 21289942
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of primary cytology and HPV DNA cervical screening.
Bistoletti P; Sennfält K; Dillner J
Int J Cancer; 2008 Jan; 122(2):372-6. PubMed ID: 17935124
[TBL] [Abstract][Full Text] [Related]
8. The health and economic effects of HPV DNA screening in The Netherlands.
Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
10. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
13. A Model Approach for Assessing the Benefits of HPV Testing against Cytology in Screening for Cervical Cancer Precursors in Thailand.
Tantitamit T; Termrungruanglert W; Khemapech N; Havanond P
Asian Pac J Cancer Prev; 2017 May; 18(5):1271-1275. PubMed ID: 28610413
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England.
Bains I; Choi YH; Soldan K; Jit M
Int J Gynecol Cancer; 2019 Apr; ():. PubMed ID: 31018938
[TBL] [Abstract][Full Text] [Related]
15. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
16. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2012 Jun; 156(12):880-91, W312. PubMed ID: 22711081
[TBL] [Abstract][Full Text] [Related]
17. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
18. Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials.
Pileggi C; Flotta D; Bianco A; Nobile CG; Pavia M
Int J Cancer; 2014 Jul; 135(1):166-77. PubMed ID: 24302411
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
